Alerta

Inhibitors for Fra-1 and Fra-2 for use in the treatment of organ or tissue fibrosis

Resumen de: US20260234614A1

Inhibitors, pharmaceutical compositions and methods for inhibiting the expression of Fos-related antigen-1 (Fra-1) or Fos-related antigen-2 (Fra-2) in fibrogenic tissue cells for use in the treatment or prevention of organ or tissue fibrosis. The inhibitor of the present invention is characterized in that it interferes with Fra-1 or Fra-2 expression, resulting in a reduction in the amount of Fra-1 or Fra-2 in the fibrogenic cells to levels found in non-fibrotic healthy cells or tissues.

AFFIBODY MICELLE DRUG CONJUGATE

Resumen de: US20260232835A1

A copolymer includes a copolymer X and a target-specific molecule bonded to the copolymer X. The copolymer X includes structural units of formulas (A), (B) and (C),where R1, R2, and R3 are the same or different and are hydrogen or C1-3 alkyl, R4 is C1-3 alkyl, R5 is hydrogen, C1-18 alkyl, a 3- to 8-membered cycloalkyl optionally having a substituent, an adamantyl, a C6-18 aryl optionally substituted, or a 5- to 10-membered heteroaryl group optionally substituted, X1, X2, and X3 are the same or different and are oxygen, sulfur, or N—R7, R6 is hydrogen, leaving group, or linker, R7 is hydrogen or C1-3 alkyl group, m is 1 to 100, and n is 0 to 3.

DRUG DELIVERY SYSTEMS AND METHODS COMPRISING POLYSIALIC ACID AND/OR OTHER POLYMERS

Resumen de: US20260232602A1

0000 The present invention generally relates to particles, including nanocapsules or other nanoentities, comprising a polymer such as polysialic acid. The particles are able to access the interior of the cells, and/or to procure the intracellular release of the associated drugs. In one aspect, the present invention is directed to nanocapsules or other entities having an exterior or surface comprising a polymer such as polysialic acid. In some cases, targeting moieties such as Lyp-1 or (Lyp-1 peptide are bonded to the polymer, e.g., using aminoalkyl (C<1>-C<4>) succinimide or other linkers. These may be created, for example, by reacting a carboxylate moiety on a polymer with an aminoalkyl maleimide (C<1>-C<4>) or an aminoalkyl (C<1>-C<4>) methacrylamide, and reacting the resulting aminoalkyl (C<1>-C<4>) maleimide or the aminoalkyl (C<1>-C<4>) methacyrlamide to a cysteine or other sulfur group. Targeting moieties are bonded to the polymer, for example, by reacting a carboxylate moiety on a polymer with a N-hydroxysuccinimide or a carbodimide, and reacting the intermediate formed with a lysine or arginine group on a targeting peptide to produce polymer-amide-peptide. Other aspects of the invention are generally directed to methods of making or using such compositions, kits including such compositions, or the like.

COMPOSITIONS TARGETING KLKB1 AND METHODS OF USE THEREOF

Resumen de: US20260232843A1

Disclosed are methods and compositions for functional genetic modifications at selected genomic sites such as KLKB1 gene. Also provided are cell populations, which comprise the functional genetic modification at one or more selected gene loci.

Genomic Safe Harbors for Genetic Therapies in Human Stem Cells and Engineered Nanoparticles to Provide Targeted Genetic Therapies

Resumen de: US20260234671A1

Genomic safe harbors (GSH) for genetic therapies in human stem cells and engineered nanoparticles to provide targeted genetic therapies are described. The GSH and/or associated nanoparticles can be used to safely and efficiently treat a variety of genetic, infectious, and malignant diseases.

METHODS FOR PREPARING PARTICLES AND RELATED COMPOSITIONS

Resumen de: US20260232604A1

Methods for preparing particles and related compositions are provided. In some embodiments, the particles include at least one polynucleotide (e.g., mRNA), and in certain embodiments, the particles may include at least one ionizable molecule (e.g., a lipid). A method for preparing a suspension including the particles may comprise one or more filtration steps. In some such embodiments, prior to or during filtration, one or more properties of the particles (e.g., surface charge) and/or one or more properties of the suspension (e.g., pH) may be altered. In some embodiments, altering one or more properties of the particles and/or suspension may improve yield, improve a characteristic of the resulting composition, and/or prevent or reduce certain problems, such as fouling during the filtration process.

イオン化可能なチオ脂質及びその使用

Resumen de: WO2025027089A1

The present disclosure provides a compound of formula (I): (I), or a pharmaceutically acceptable salt thereof, that is useful for forming particles (e.g., lipid nanoparticles) for delivery of nucleic acids. The present disclosure further provides particle compositions comprising the compound of formula I, as well as uses thereof.

マイクロＲＮＡデターゲティングセンサーを含むポリヌクレオチド及びその使用

Resumen de: WO2025024704A1

The present disclosure relates to polynucleotides comprising (a) a first region encoding a payload and (b) a second region comprising an immune cell detargeting sensor (e.g., a spleen detargeting sensor). Upon recognition of the marker by the sensor, the expression of the encoded payload is reduced or inhibited. Also provided herein are replicons, nanoparticles, synthetic circuits, pharmaceutical compositions comprising such polynucleotides. Methods of using the polynucleotides, replicons, synthetic circuits, nanoparticles, and pharmaceutical compositions are also provided.

NANOPARTICLE COMPOSITIONS FOR TARGETED DELIVERY TO CARTILAGE AND RELATED METHODS

Resumen de: WO2026170199A2

The present disclosure provides therapeutic matrix inverse targeting (MINT) nanoparticle including a MINT nanoparticle and a therapeutic material encapsulated in the MINT nanoparticle. The MINT nanoparticle includes a biocompatible polymer and an anionic coating. The disclosure further provides compositions including such a nanoparticle and methods of making such a nanoparticle or compositions. The disclosure further provides a method of treating an articular cartilage disease characterized by a decrease in glycosaminoglycan in extracellular matrix of articular cartilage using such a nanoparticle or composition.

SENESCENCE-ASSOCIATED NANOPARTICLE; FORMULATIONS, METHODS, AND USES THEREOF

Resumen de: WO2026167555A1

The present disclosure relates to a senescence-associated beta-galactosidase (SA-β-Gal) degradable polymeric nanoparticle, formulations, methods of producing said nanoparticle and uses in senotherapy. Said nanoparticle is capable of precisely and efficiently deliver and release a senotherapeutic active ingredient, namely a senolytic active ingredient, in organ-specific senescent cells, particularly the senescent liver cells, increasing the senotherapeutic index of the senolytic active ingredient and inducing apoptosis in senescent cells overexpressing SA-β-Gal.

BRAIN TARGETED NANOCONJUGATES AND USES THEREOF

Resumen de: WO2026169706A1

The disclosure relates to nanoconjugates and uses thereof. Specifically, the disclosure provides nanoconjugates comprising a biodegradable polymeric backbone conjugated to a blood-brain barrier penetrating peptide and an immunotherapeutic agent, and uses thereof for treating cancers of the central nervous system.

PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DIABETES COMPRISING NANOVESICLES DERIVED FROM JERUSALEM ARTICHOKE AS ACTIVE INGREDIENT

Resumen de: WO2026169105A1

The present invention relates to a pharmaceutical composition for preventing or treating diabetes comprising nanovesicles derived from Jerusalem artichoke (Helianthus tuberosus) as an active ingredient. The nanovesicles derived from Jerusalem artichoke exhibit a blood sugar reduction effect and a collagen synthesis inhibition effect, which are confirmed to be superior to those of Jerusalem artichoke extract, and thus the composition can be effectively utilized as a composition for preventing, treating or improving diabetes.

DEXAMETHASONE SODIUM PHOSPHATE LOADED NANOPARTICLES FOR PREVENTION AND TREATMENT OF VESICANT AGENT INDUCED OCULAR INJURY

Resumen de: WO2026169809A1

Provided herein are methods of preventing and/or treating vesicant agent induced ocular injury. The methods comprise treating the eyes of a subject injured or at risk of being injured by a vesicant agent with dexamethasone sodium phosphate (DSP) loaded nanoparticles. In some aspects, the vesicant agent is mustard gas.

医薬剤のポリマー対応送達

Resumen de: WO2025000039A1

Disclosed herein is a bioactive polymer for forming a solution and/or hydrogel to stabilise one or more pharmaceutically active agents prior to, during or post-administration, the polymer comprising a first monomer for binding water, a second monomer for imparting mechanical properties to the scaffold; optionally, a third monomer for binding to a natural or synthetic peptide or protein (NSPP); and a fourth monomer for imparting phase-transition behaviour. Preferably, the first monomer is OEGMA; the second monomer is PLA/HEMA; the third monomer is NAS; and the fourth monomer is NIPAAm, and the polymer comprises: OEGMA in an amount of from about 1 to about 15 mol%; PLA/HEMA in an amount of from 5 to about 50 mol%; NAS in an amount of from 0 to about 15 mol%; and NIPAAm in an amount of up to about 85 mol%.

COMPOSITION AND METHOD OF USE FOR A THERAPEUTIC NANOLIGOMER

Resumen de: US20260232813A1

0000 A therapeutic nanoligomer composition includes at least a peptide nucleic acid (PNA), the at least a PNA including a sequence of nucleobases capable of interacting with a gene target in a target host and a polypeptide backbone attached to the sequence of nucleobases, the polypeptide backbone including a plurality of amino acid units, wherein the plurality of amino acid units includes at least a 2-N-aminoethylglycine unit; and a transport domain, the transport domain including a delivery nanoparticle and a cellular uptake domain (CUD) associated with the delivery nanoparticle, wherein the delivery nanoparticle is attached to the at least a PNA, and wherein the CUD includes a hydrophilic polymeric coating or one or more weakly charged surface groups.

Peptide-Conjugated Lipid Nanoparticle (LNP) Compositions and Methods for Brain-Targeted Delivery of Therapeutic Agents

Resumen de: US20260232836A1

The present disclosure relates, in part, to polypeptide-conjugated lipid nanoparticle (LNP) compositions, and methods of use thereof for brain-targeted delivery of therapeutic cargo. In another aspect, the disclosure provides methods for treating, preventing, and/or ameliorating disease and/or disorders of the brain (e.g., neurological disease and/or disorders).

SYNTHETIC MELANIN NANOPARTICLES FOR PROTECTION OF CELL-FREE REACTIONS

Resumen de: US20260232838A1

Provided herein are synthetic melanin nanoparticles and methods useful for protecting cell-free reactions from prolonged solar and UV exposure.

PEPTIDE SEQUENCE AND METHODS FOR ATHEROSCLEROTIC PLAQUE TARGETING

Resumen de: WO2026169269A2

Provided herein are compositions comprising peptide-based nanoparticles. In some embodiments, the peptide-based nanoparticles each comprise a perfluorocarbon liquid core and a plurality of amphiphilic peptides surrounding the perfluorocarbon liquid core. In some embodiments, the amphiphilic peptides comprise a peptide analogue of Apolipoprotein A1. Also provided herein are methods of preparing any of the compositions described herein, as well as methods of treating atherosclerotic plaque formation using any of the composition described herein.

LIPID NANOPARTICLES, METHODS OF MAKING LIPID NANOPARTICLES, AND USES THEREOF

Resumen de: WO2026169723A1

The present disclosure provides, among other things, improved lipid nanoparticles and improved methods of making lipid nanoparticles.

Compositions and Methods for Treating Wound Healing and Hypothermia

Resumen de: US20260232806A1

0000 Aspects describe nanoparticle-delivered adenyl cyclase activators (e.g., forskolin via LCMSN) to induce sWAT browning, enhancing thermogenesis for wound healing and cold injury protection. Applications include chronic wounds, diabetic ulcers, burns, frostbite, and hypothermia via subcutaneous or transdermal routes, with demonstrated acceleration of closure, reduced inflammation/necrosis, and improved angiogenesis/ECM remodeling in frostbite models.

CATIONIC OR IONIZABLE LIPIDS AND USES THEREOF

Resumen de: WO2026166986A1

The present disclosure provides a compound of formula I: I or a pharmaceutically acceptable salt thereof, that is useful for forming particles (e.g., lipid nanoparticles) for delivery of nucleic acids. The present disclosure further provides particle compositions and suspensions comprising the compound of formula I, as well as uses thereof.

LIPID COMPOUNDS, COMPOSITIONS, AND USES THEREOF

Resumen de: US20260234115A1

0000 The present disclosure provides lipid compounds and compositions (e.g., lipid nanoparticle (LNP) compositions) comprising lipid compounds of the present disclosure. The present disclosure provides methods of delivering an active agent (e.g., polynucleotide) to a cell or tissue in a subject, preferably an extrahepatic cell or tissue, comprising administering to the subject an effective amount of a lipid nanoparticle of the present disclosure, wherein the lipid nanoparticle comprises lipid compounds of the present disclosure and the active agent (e.g., polynucleotide).

Substantially Monodisperse Ultrasound Responsive Nanobubble Compositions and Methods of Production and Use Thereof

Resumen de: US20260232849A1

0000 Compositions, methods, and kits relating to substantially monodisperse, ultrasound targeted nanobubble compositions are disclosed. The nanobubble compositions comprise a hollow core containing at least one gas and a polymer shell encircling the hollow core. Methods of producing the substantially monodisperse nanobubble compositions using an ultrasound shearing-based fabrication method are disclosed. Methods of using the nanobubble compositions are also disclosed.

BUBBLE PREPARATION, AND TUMOR SUPPRESSION AND DRUG DELIVERY SYSTEM EACH USING BUBBLE PREPARATION

Resumen de: WO2026168562A1

Problem To provide a bubble preparation capable of significantly suppressing a tumor and efficiently delivering a drug or the like to a site such as a tumor when used together with low-intensity therapeutic ultrasound. Solution A bubble preparation which exhibits a tumor suppressing effect when low-intensity therapeutic ultrasound is applied to the bubble preparation, the bubble preparation being characterized by comprising a coating film, which comprises a lipid, and a gas enclosed in the lumen of the coating film, wherein the coating film is an anionic lipid containing at least distearoylphosphatidylcholine (DSPC) and distearoylphosphatidylglycerol (DSPG), and the gas contains at least one of perfluoropropane, perfluorobutane, perfluoropentane, and perfluorohexane, or a mixed gas.

VACCINE COMPOSITION AND METHODS FOR INDUCING IMMUNITY AGAINST MYCOBACTERIUM TUBERCULOSIS

Nº publicación: WO2026169218A1 13/08/2026

Solicitante:

MAHIDOL UNIV [TH]
MAHIDOL UNIVERSITY